8-K: Nexalin Acquires AI Health Platform for HALO Clarity

Nexalin Technology acquires PONM, Inc. to integrate AI-driven digital health platform supporting its HALO Clarity program and NeuroCare virtual clinic.

Summary

• Nexalin Technology, Inc. has acquired PONM, Inc. for $1.3 million in company stock, payable in tranches.
• This acquisition includes PONM's digital health platform, which supports Nexalin's HALO Clarity program and NeuroCare virtual clinic.
• The platform features AI-integrated remote patient monitoring, clinical data capture, and virtual-clinic management.
• The technology is already deployed at the University of California, San Diego (UCSD) for clinical research and patient monitoring.
• This move aims to give Nexalin greater control over its digital infrastructure, crucial for its planned FDA pivotal trial and future commercialization.
• A strategic partnership with GreenLight Ventures LLC, the seller of PONM, has also been established to provide ongoing support.
• The acquisition was completed on May 14, 2026, with an initial tranche of shares issued.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as the acquisition strengthens Nexalin's control over its technology ecosystem and is strategically aligned with its clinical and commercial goals.

Positives

• Acquisition of a critical AI-integrated digital health platform (PONM) that enhances control over the HALO Clarity ecosystem.
• Secures exclusive license to proprietary software features for AI-enabled remote patient monitoring, data capture, and virtual clinic management.
• The acquired technology is already deployed and validated at UCSD, supporting clinical research and patient workflows.
• Strengthens Nexalin's ability to execute its planned FDA pivotal trial and future regulatory strategy.
• Establishes a strategic partnership with GreenLight Ventures for continued product, engineering, and regulatory support.
• Aligns GreenLight Ventures as a meaningful equity holder and long-term partner, incentivizing shared success.

Negatives

• The total consideration of $1.3 million is payable in Nexalin common stock, issued in tranches, which could lead to dilution.
• The acquisition is subject to risks associated with integrating and scaling the acquired technology and ensuring its security and validation.
• Reliance on GreenLight Ventures for ongoing support under the strategic partnership.

Risks

• The ability to successfully integrate, maintain, secure, validate, and scale the PONM platform and its AI-enabled systems.
• Uncertainties regarding the design, enrollment, execution, timing, results, and completion of clinical trials, including the HALO Clarity pivotal program.
• The ability to obtain regulatory clearance or approval from the FDA or other regulatory bodies.
• Potential for adverse events, safety concerns, or product performance issues with the HALO Clarity device and its associated platform.
• Market acceptance of, and reimbursement for, Nexalin's products.
• Competition from existing and new treatment alternatives.
• Reliance on third parties, including GreenLight, UCSD, and other vendors.
• The sufficiency of funding to complete planned clinical, regulatory, and commercial programs.

Future Outlook

Nexalin anticipates that the acquisition of PONM and the strategic partnership with GreenLight will strengthen its ability to execute through pivotal trial activities, planned FDA submission, and potential commercial launch of HALO Clarity. The company believes the integrated device-plus-software model is important for its future regulatory strategy and commercial deployment.

Management Comments

• "This acquisition gives Nexalin ownership of a critical part of the HALO Clarity ecosystem: the digital platform that connects the device, the patient, the physician and the clinical-data workflow," said Mark White, Chief Executive Officer of Nexalin Technology.
• "The PONM platform is already deployed at UCSD and supports the AI-integrated remote-monitoring, clinical-data capture and virtual-clinic capabilities we believe are essential to scaling HALO Clarity."
• "We believe combining HALO Clarity with AI-enabled data infrastructure can strengthen treatment oversight, improve protocol adherence and create a scalable foundation for future physician-supervised, at-home neurostimulation programs."
• "We believe the future of neurostimulation will be defined not only by the device itself, but by the software, data and physician-supervised care model around it," continued Mr. White.
• "This transaction strengthens Nexalins control over that full ecosystem and expands what we believe the Company can ultimately offer to patients and providers seeking non-invasive treatment alternatives."
• "With this transaction, Nexalin has the exclusive rights to the platform, while GreenLight remains aligned as both a long-term partner and shareholder."

Industry Context

StockSavvy.ai notes that this acquisition aligns with the growing trend in the digital health and medical device sectors towards integrated solutions. Companies are increasingly focusing on combining hardware with sophisticated software, AI, and data analytics to enhance patient outcomes, improve clinical trial efficiency, and create scalable commercial models. This move by Nexalin positions it to compete more effectively in the neurostimulation market by controlling the full digital ecosystem.

Comparison to Industry Standards

• The integration of AI-driven remote patient monitoring and virtual clinic capabilities is becoming a standard expectation for advanced medical technologies, particularly in areas like mental health and neurological disorders.
• Companies like Pear Therapeutics have pioneered digital therapeutics, demonstrating the market potential for software-based interventions, though facing challenges in reimbursement and scalability.
• The use of AI for real-time clinical data analysis and treatment adherence monitoring is a key differentiator, aiming to improve patient outcomes and streamline clinical research, a practice being adopted by leading pharmaceutical and biotech firms.
• The model of physician-supervised, at-home therapy, supported by robust digital infrastructure, is seen as the future direction for many chronic condition management solutions.

Related Party Transactions

• The acquisition of PONM, Inc. from GreenLight Ventures LLC, where GreenLight Ventures LLC is a seller and becomes a significant equity holder and strategic partner.
• The Collaboration Agreement with GreenLight Ventures LLC for development and infrastructure support services, with a monthly fee of $10,000.

Stakeholder Impact

• Shareholders: Potential for increased long-term value if the acquisition and subsequent development of HALO Clarity are successful, but also potential dilution from stock issuances.
• Employees: Enhanced job security and opportunities as the company advances its technology and commercialization efforts.
• Patients: Potential access to a novel, non-invasive treatment for insomnia and other neurological conditions through a physician-supervised, at-home model.
• Physicians: Access to an integrated platform for patient monitoring, data analysis, and treatment oversight, potentially improving patient management.
• Creditors: The company's ability to secure future funding remains critical for ongoing operations and development.

Next Steps

• Complete the integration of the PONM platform into Nexalin's HALO Clarity program.
• Proceed with the planned 160-participant FDA pivotal trial for HALO Clarity for moderate-to-severe insomnia, with enrollment expected to begin in Q2 2026.
• Prepare for future regulatory submissions, including a potential De Novo FDA submission.
• Continue development and commercialization efforts for HALO Clarity and Nexalin NeuroCare.
• File Nexalin's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which will include the full text of the Stock Purchase Agreement as an exhibit.

Key Dates

Recommendation

The acquisition is a strategically sound move that strengthens Nexalin's technological foundation and its path towards FDA approval and commercialization. However, significant execution risks remain, including clinical trial success, regulatory approval, market adoption, and the need for future funding. While positive, the inherent uncertainties warrant a 'hold' recommendation until further progress is demonstrated.

Keywords

Nexalin Technology, PONM, HALO Clarity, AI, Digital Health, Remote Patient Monitoring, Virtual Clinic, Acquisition